Latest Information Update: 16 Jul 2016
At a glance
- Originator LEO Pharma
- Class Antipsoriatics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Plaque psoriasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Plaque-psoriasis in France (Topical, Ointment)
- 24 Feb 2011 Phase-I clinical trials in Plaque psoriasis in France (Topical)